Featured Research

from universities, journals, and other organizations

Iowa Researchers Identify Prostate Tumor Suppressor

Date:
August 3, 1999
Source:
University Of Iowa
Summary:
University of Iowa Health Care researchers may have found a way to prevent prostate cancer from spreading, according to research findings in the Aug. 1 issue of the journal Cancer Research.

IOWA CITY, Iowa -- University of Iowa Health Care researchers may have found a way to prevent prostate cancer from spreading, according to research findings in the Aug. 1 issue of the journal Cancer Research.

The UI team, led by Mary J.C. Hendrix, Ph.D., professor and head of anatomy and cell biology; her graduate student, Jun Luo; and collaborator David M. Lubaroff, Ph.D., UI professor of urology, found that restoring a lost or decreased protein called E-cadherin hinders the ability of prostate cancer to spread.

"The results of this study provide a potential new therapeutic strategy for targeting invasive prostate cancer," said Hendrix, the associate director of basic research and deputy director for the UI Cancer Center.

"The correlation between the expression of the E-cadherin protein and the spreading of prostate cancer to distant sites may provide another weapon in the battle against this deadly disease," added Lubaroff, the associate director for research infrastructure for the UI Cancer Center.

Prostate cancer is the most commonly diagnosed cancer and is the second leading cause of cancer death in American men. Although most of the time the cancer is diagnosed and treated at early stages, some tumors do spread.

"The progression of the disease involves a number of steps, including discrete molecular changes," Hendrix explained. "It is crucial to identify the molecular changes and understand how they fit into the disease progression in order to develop better therapeutic approaches to manage prostate cancer."

Hendrix and her colleagues knew from previous studies that disruptions in the E-cadherin complex were commonly associated with many advanced forms of cancer. E-cadherin is an important intercellular adhesion molecule that helps to maintain the integrity of normal epithelial cells.

With data from laboratory experiments and clinical biopsies, UI researchers and other investigators elsewhere had suggested there was a correlation between the decreased E-cadherin and the ability of prostate cancer to spread. However, until this most recent UI study, there was no direct evidence to support the idea that genetic reintroduction of E-cadherin could suppress prostate cancer invasion.

Using prostate cancer cells from a rat model, the UI investigators restored missing or deficient E-cadherin in the cells. The results showed that the strategy drastically enhanced the ability of the prostate cancer cells to adhere to each other, thus restoring their epithelial integrity. The approach also suppressed the release of enzymes known to participate in cancer invasion through organs and tissues in the body.

The UI team is now involved in gene therapy studies to reintroduce E-cadherin into prostate cancer cells to inhibit the ability of these cells to invade and spread.

"The outcome of these studies could form the basis of the development of new clinical strategies for the treatment of prostate cancer," Hendrix said.

Richard D. Williams, M.D., UI professor and head of urology added: "This study is a prime example of the enormous potential that molecular biologic techniques have to change the behavior of cancer cells. When directly applied to patients, this discovery raises great hope of limiting the spread of prostate cancer within the body and thus improving survival."


Story Source:

The above story is based on materials provided by University Of Iowa. Note: Materials may be edited for content and length.


Cite This Page:

University Of Iowa. "Iowa Researchers Identify Prostate Tumor Suppressor." ScienceDaily. ScienceDaily, 3 August 1999. <www.sciencedaily.com/releases/1999/08/990803073522.htm>.
University Of Iowa. (1999, August 3). Iowa Researchers Identify Prostate Tumor Suppressor. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1999/08/990803073522.htm
University Of Iowa. "Iowa Researchers Identify Prostate Tumor Suppressor." ScienceDaily. www.sciencedaily.com/releases/1999/08/990803073522.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins